2310 Alfred-Nobel Boulevard
QC H4S 2B4
Canada - Map
Theratechnologies Inc., a biopharmaceutical company, develops and commercializes therapeutic peptide products. The companys lead product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the United States. It also focuses on commercializing EGRIFTA in Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, Thailand, and certain central Asian countries. Theratechnologies Inc. also has TH1173, a second-generation GRF peptide that has completed preclinical studies in its product pipeline. The company was founded in 1993 and is headquartered in Montréal, Canada.
|Mr. Luc Tanguay M.Sc., C.F.A.,
Chief Exec. Officer, Pres and Non-Independent Director
|Ms. Marie-No Colussi C.A.,
VP of Fin.
|Mr. Christian Marsolais Ph.D.,
Sr. VP of Scientific Affairs and Alliances
|Mr. Jocelyn Lafond LL.B., L.L.M.,
VP of Legal Affairs and Sec.
|Mr. Pierre Perazzelli B.Sc. ,
VP of Pharmaceutical Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in CAD.|